Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H21ClN2OS.ClH |
Molecular Weight | 397.362 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCC(=O)N1C2=CC(Cl)=CC=C2SC3=C1C=CC=C3
InChI
InChIKey=QELDTSNVBZMBTQ-UHFFFAOYSA-N
InChI=1S/C19H21ClN2OS.ClH/c1-3-21(4-2)12-11-19(23)22-15-7-5-6-8-17(15)24-18-10-9-14(20)13-16(18)22;/h5-10,13H,3-4,11-12H2,1-2H3;1H
Molecular Formula | C19H21ClN2OS |
Molecular Weight | 360.901 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Chloracyzine is phenothiazine derivative with vasodilatory activity. Chloracyzine produced a decrease in myocardial oxygen consumption accompanied by a reduction in coronary blood flow preceded by transient coronary dilatation. Chloracyzine produced an insignificant increase in arterial pressure; heart rate increased slightly in the open-chest experiments but not in the isolated heart. It is suggested that reduced oxygen uptake after chloracyzine is realized through improved efficiency in the use of oxygen.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:23:25 GMT 2023
by
admin
on
Sat Dec 16 07:23:25 GMT 2023
|
Record UNII |
3R20PI460D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3R20PI460D
Created by
admin on Sat Dec 16 07:23:25 GMT 2023 , Edited by admin on Sat Dec 16 07:23:25 GMT 2023
|
PRIMARY | |||
|
DTXSID40909008
Created by
admin on Sat Dec 16 07:23:25 GMT 2023 , Edited by admin on Sat Dec 16 07:23:25 GMT 2023
|
PRIMARY | |||
|
m3338
Created by
admin on Sat Dec 16 07:23:25 GMT 2023 , Edited by admin on Sat Dec 16 07:23:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
1045-82-5
Created by
admin on Sat Dec 16 07:23:25 GMT 2023 , Edited by admin on Sat Dec 16 07:23:25 GMT 2023
|
PRIMARY | |||
|
213-877-1
Created by
admin on Sat Dec 16 07:23:25 GMT 2023 , Edited by admin on Sat Dec 16 07:23:25 GMT 2023
|
PRIMARY | |||
|
160559
Created by
admin on Sat Dec 16 07:23:25 GMT 2023 , Edited by admin on Sat Dec 16 07:23:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |